Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors

Reaz Uddin a,4, Khurshid Jalal b, Kanwal Khan a, Zaheer ul-Haq a

a Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Lab 103 PCMD ext., Karachi 75270, Pakistan
b H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan

A R T I C L E   I N F O

Article history:
Received 10 September 2021
Revised 19 October 2021
Accepted 10 November 2021
Available online 19 November 2021

Keywords:
Mpro protease
Protease inhibitors
SARS-CoV-2
Drug re-purposing
Hepatitis C Virus
Direct Acting Antivirals (DAAs)

A B S T R A C T

A new coronavirus strain called SARS-CoV-2 has emerged from Wuhan, China in late 2019 and it caused a worldwide pandemic in a few months. After the Second World War, it is the biggest calamity observed as there is no specific US Food and Drugs Administration (USFDA) approved drug or vaccine available globally for the treatment. Several clinical trials are ongoing for therapeutic alternatives, however with little success rate. Considering that the time is crucial, the drug repurposing and data obtained from in silico models are one of the most important approaches to identify possible lead inhibitors against SARS-CoV-2. More recently, the Direct Acting Antivirals (DAAs) are emerged as the most promising drugs to control viral infection. The Main Protease (Mpro), a key enzyme in the SARS-CoV-2 replication cycle, is found close homolog to the Hepatitis C Virus (HCV) protease and could be susceptible of blocking its activity by DAAs. In the current study, the DAAs were investigated as antivirals using structure based computational approach against Mpro of SARS-CoV-2 to propose them as new therapeutics. In total, 20 DAAs of HCV, including a reference compound O6K were docked against Mpro. The docked structures were examined and resulted in the identification of six highly promising DAAs i.e. beclabuvir, elbasvir, paritaprevir, grazoprevir, simeprevir, and asunaprevir exhibiting high theoretical binding affinity to Mpro from SARS-CoV-2 in comparison to other DAAs. Furthermore, the post docking analysis revealed that Cys145, Glu166, His163, Thr26, His41, and Met165 played potential role for the binding of these DAAs inside binding site of Mpro. Furthermore, the correlation between binding energies were found in accord with the results from the reported IC50s for some DAAs. Overall, the current study provides insight to combat COVID-19 using FDA-approved DAAs as repurposed drugs.

© 2021 Elsevier B.V. All rights reserved.

1. Introduction

An acute respiratory disease that is causing progressive lung injury was reported to World Health Organization (WHO) in the late 2019. The disease was first detected from Wuhan (China) and subsequently announced as new coronavirus disease. It was labelled as COVID-19 in February 2020 [20]. The COVID-19 is responsible for more than 10 million infected cases, and more than 450,000 deaths just in few months from 196 countries (the number is still progressing). Therefore, the World Health Organization (WHO) declared SARS-CoV-2 as the new coronavirus as a global pandemic on March 11, 2020 [26]. The world has been battling with this highly infectious COVID-19 disease for more than two years i.e. ~131,965,495 positive cases and 2867,083 deaths (as of April 05, 2021) worldwide. Furthermore, recent studies indicated that COVID-19 not only affects the lung tissues but also exhibits adverse effects on the other organs such as heart, brain and kidneys, thus indicating that potent anti-COVID-19 agent should possess a tendency toward these target organs. Current prevention is based on quarantine to prevent its transmission. However, many promising treatments are yet to complete their clinical trials [1]. Although WHO approved vaccines (i.e. Sinopharm, Sinovac, Pfizer, AstraZeneca and many others) are being used for the time being, still certain side effects (such as blood clotting etc.) are reported related to specific vaccine. Therefore, more therapeutics are urgently required for this fast-moving pandemic so that the world is prepared for next COVID-19 wave. An extensive effort is being performed from researchers around the world to combat this virus.

The SARS-CoV-2 is a positive-sense single-stranded RNA virus belongs to the same family as SARS-CoV, i.e. coronaviridae. It has a largest genome among other known RNA viruses [26]. Its replication mechanism requires a number of key enzymes, notably helicases, main protease (Mpro) and RNA-dependent RNA-polymerase

https://doi.org/10.1016/j.molstruc.2021.131920
0022-2860/© 2021 Elsevier B.V. All rights reserved.
(RdRp). It is consisting of six Open Reading Frames (ORFs) [27]. The first ORF (ORF1a/b) is composed of two-third of RNA genome and encodes for two poly peptides i.e. pp1a and pp1ab while the remaining five ORFs make up of one-third of RNA genome responsible for the production of membrane protein (M), envelope protein (E), nucleocapsid protein (N) and spike protein (S) [12]. Likewise, Hepatitis C virus is also a positive-sense single-stranded RNA virus belongs to the Flaviviridae family. It is classified into eight different major genotypes. The NS3 mediates the production of protease, NS4A/B mediates four polyproteins cleavage events while NS5A/B encodes for the polymerases for viral cycle. It is observed that HCV proteins share the similar genomic construction as SARS-CoV-2 (Fig. 1) [3].

However, the two poly peptides generated from first ORFs (pp1a and pp1ab) encodes for a number of viral Nonstructural Proteins (NSPs), among which is NS5P (a cysteine 3C-like protease) known as main protease (Mpro). The Mpro protein mediates the production of important NSPs crucial for the viral infection cycle i.e. RNA-dependent RNA polymerase, methyltransferase, and helicase [24]. Hence, the main protease controls the major pathways and replication of viral genome, it can be used as attractive drug target to halt the replication event in the virus life cycle [18]. It is three-domain (domains I to III) cysteine protease having active site between domains I and II. The main protease (NS3) of HCV is a chymotrypsin-like serine protease [2]. Recently developed highly effective therapeutics of HCV are the inhibitors of this protease. The combination of antivirals especially DAAs that directly targets the HCV proteins share the similar genomic construction as SARS-CoV-2 (Fig. 2). These similarities have led to the investigation of existing HCV Direct Acting Antiviral (DAA) against COVID-19 as potential therapies [6]. The DAAs are effective antivirals used against HCV protease and HCV polymerase and RNA-dependent RNA polymerase [11]. Several combination of DAAs are approved by Federal Drug Authorities (FDA) and European Medicine Agency (Mengist et al.) for the HCV as pan-genotypic treatment [21]. Recently, the concept of drug re-purposing has been widely used because of the drugs approved for one disease have considerable advantage in terms of time and cost, pharmacokinetics and toxicity being investigated in humans [4]. The drug re-purposing is one of the promising approaches in recent days to bring about innovative cures by the existing FDA approved drugs [9].

Therefore, the current study was aimed to identify the candidate drugs using a computational approach of molecular docking.

For this purpose, a library of FDA-approved Hepatitis C DAAs drugs was investigated to find their potential for re-purposing as anti-SARS-CoV-2 drugs against Mpro.

2. Material and methods

In the current study, an in-silico based molecular docking approach was applied for the DAAs of HCV for the prioritization of novel drug candidates against SARS-CoV2. The complete work flow of the current study is presented in Fig. 3.

2.1. Protein retrieval

The COVID-19 main protease (PDB ID: 6Y2G) was obtained from the Protein Data Bank [22] in PDB format. The protein contained two chains (A, and B), having a sequence length of 306 amino acids. The 6Y2G protein was incorporated with ligand i.e. ID 06 K, IUPAC Name: ~[(tert]-butyl ~[N]-[1-[(2~[S]-3-cyclopropyl-1-oxidanylidene-1-[[2~[S],3~[R]-3-oxidanyl-4-oxidanylidene-1-[[3~[S]]-2-oxidanylidenedeyrrolidin-3-yl]-4-[(phenylmethyl)amino][butan-2-yl]amino][propan-2-yl]-2- oxidanylidene-pyridin-3-yl]carbamate.

2.2. Direct Acting Antivirals retrieval

The 20 FDA reported DAAs (beclabuvir, boceprevir, dasabuvir, glecaprevir, paritaprevir, pibrentasvir, ribavirin, ritonavir, telaprevir, velpatasvir, asunaprevir, voxilaprevir, daclatasvir, elbasvir, faldaprevir, omitsavir, grazoprevir, simeprevir, sofosbuvir, and ledipasvir) were obtained from the DrugBank [25] (Fig. 4). The selected dataset of 20 compounds exhibited considerable activity against HCV. Table 1 showed the dataset of selected DAAs.

2.3. Protein preparation

The obtained protein crystal structure was prepared and further refined for molecular docking study. The water molecules were removed while polar hydrogens were added to PDB structure. Kollam united atom force field was used to add charges to protein structure by AutoDock 4.2 [10,19]. Then the structure was saved in a PDBQT format for further molecular docking calculations.

Fig. 1. Schematic representation of SARS-CoV-2 (left) and Hepatitis C virus (Right) genome. The genome structure represents a ORF1a (Open Reading Frame a) encodes for nspl-nsp10, ORF1b encodes for nspl–nsp16, while Spike protein (S), Envelope gene (E), membrane gene (M), Nucleocapsid gene and a poly (A) tail at the 3’ UTR (four genes) encode for the structural proteins. Additionally, the accessory genes are distributed in between the structural genes (i.e. 3a, 7a, 7b, 6, and 8).

Fig. 2. Frames of Table 1. The Table 1 contains the list of DAAs used in the current study with their structure, names and source. The DAAs are classified into three categories: A) Approval date, B) Known sources, C) Number of clinical trials, and D) Clinical status.

Table 1. List of DAAs used in the current study with their structure, names, and source. The DAAs are classified into three categories: A) Approval date, B) Known sources, C) Number of clinical trials, and D) Clinical status.
2.4. Ligand preparation

The DAAs library used as ligands for this study was processed and prepared for docking studies. The retrieved PDB structures were energy minimized through Frog2 tool [17]. The minimized 20 DAAs were further analyzed via AutoDock and the gasteiger charges were computed. The saved PDBQT files were used for docking analysis.

2.5. Receptor grid preparation

The grid box for Mpro was generated through AutoDock tool [10,19], around the active site defined by already co-crystalized ligands present in PDB structure with the binding pocket. The grid box dimensions were generated as point 46, 48, and 50 for X, Y, and Z dimensions while the Grid Box center was set as -19.942, -6.232, and -26.819 for X, Y, and Z center, respectively.
Table 1
DAAs Of HCV used in current study.

| Inhibitors               | DAAs            | DrugBank IDs | Status                                                                 |
|--------------------------|-----------------|--------------|-------------------------------------------------------------------------|
| NS3/4A                   | Beclabuvir      | DB12225      | In trials                                                              |
| PRO-                     | Glecaprevir     | DB13879      | Recommended for HCV under Brand name Maviret, and Mavyret              |
| TEASE                    | Paritaprevir    | DB09297      | Recommended for HCV under Brand name Viekira Pak                      |
| NS5A INHIBITORS          | Boceprevir      | DB08873      | Recommended mediation                                                  |
|                          | Simeprevir      | DB06290      | 2nd Generation Recommended Drug                                        |
|                          | Grazoprevir     | DB11575      | Recommended for HCV under Brand name Epater                           |
|                          | Faldaprevir     | DB11808      | Under Investigation                                                    |
|                          | Voxelaprevir    | DB12026      | Recommended for HCV under Brand name Vosevi                           |
|                          | Asunaprevir     | DB11546      | Under Investigation                                                    |
|                          | Telaprevir      | DB05521      | Used as Combination with Ribavirin                                    |
|                          | Ledipasvir      | DB09027      | Recommended for HCV under Brand name Harvoni                          |
|                          | Velpatasvir     | DB11613      | Recommended for HCV under Brand name Epclusa, and Vosevi              |
|                          | Ribavirin       | DB00811      | Recommended for HCV under Brand name Ibasyr, Rebetol, and Virazole    |
|                          | Ritonavir       | DB00503      | Recommended for HCV under Brand name Kaletra, Norvir, and Viekira Pak  |
|                          | Daclatasvir     | DB09102      | Marketed under the name DAKLINZA                                       |
|                          | Elbasvir        | DB11574      | Recommended for HCV under Brand name Zepatier                          |
|                          | Ombitasvir      | DB09296      | Recommended for HCV under Brand name Viekira Pak                       |
|                          | Pibrentasvir    | DB13878      | Recommended for HCV under Brand name Mavirat, and Mavyret              |
| NS5B nucleoside polymerase inhibitors (NPIs) | Dasabuvir       | DB09183      | Recommended for HCV under Brand name Eculisa, Harvoni, Sovaldi, and Vosevi |
| NS5B non-nucleoside polymerase inhibitors (NNPIs) | Sofosbuvir      | DB08934      | Recommended for HCV under Brand name Exviera, Viekira Pak              |

Fig. 4. Structures of 20 DAAs used in current study against Mpro.
2.6. Molecular docking studies

Molecular docking is commonly used structure-based approach to highlight the binding mode of compounds with selected proteins in terms of Van der Waals, binding affinities, electrostatic noncovalent interactions, ligand conformations in the binding site of the macromolecule and hydrogen interaction of ligand with protein [9]. The predicted binding poses in docking study are ranked as docking scores. The 20 DAAs were used as ligand library for docking studies against Mpro protein. The molecular docking study was performed using AutoDock tool 4.2v with standard docking procedure applied [10,19]. The ligand was docked and implemented by the parameters of 250 times Lamarckian GA settings resulting in 27,000 number of generations. Furthermore, re-docking step was implemented to validate our virtual screening process with co-crystalized ligand present in the Mpro retrieved from PDB. Finally, rigid docking was performed against the active site of Mpro protein while the flexible nature of ligand was set to perform docking without forcing the ligand to the active site only. However, the binding scores and ligand binding probability to the active site of Mpro were used for the evaluation of affinity through the molecular docking study.

2.7. Re-docking process with autodock

The re-docking is performed to assess the performance of any docking program so that it is decided if the docking program is capable of reproducing the same crystal conformation of the bound ligand or not? The re-docking experiment in the case of Mpro was employed by the AutoDock with its co-crystallized ligand.

2.8. Post docking study

The MOE tool was used to investigate the docked DAAs and Mpro complex interaction to visualize the hydrogen and hydrophobic interaction of complex within the range of 5 Å.

2.9. Correlation identification

Moreover, the correlation between IC₅₀ and binding affinity was also studied for DAAs and Mpro protein. The IC₅₀s were retrieved from literature mining while the docked binding energies were predicted through AutoDock tool [7].

3. Results

3.1. Molecular docking results

The molecular docking study was carried out to analyze the binding mode of the DAAs against Mpro protein of SARS-CoV-2. The docking analysis highlights the interaction of compounds with crucial amino acids residues present at the active site with binding energies obtained from docking results are given in Table 2. The molecular docking results demonstrated in terms of negative energy and indicating that the lower the binding energy scores, best would be the binding affinity of the ligand to its receptor [13].

The docking study revealed that, Ombitasvir mediates two hydrogen bond interaction with Glu166, one hydrogen bond with Asn142 through nitrogen (NH) and Oxygen atoms of side chain, while Ser46 mediates one hydrogen – aren interaction with the aromatic ring of Ombitasvir as shown in Supplementary Fig. S1. The compound showed good anti-SARS activity with an estimated docking score of -6.85 kcal/mol.

The binding mode of Beclabuvir showed significant (highest of all other compounds) docked score i.e. -11.97 kcal/mol. It formed one hydrogen bond with Asn142 residue through its carbonyl oxygen. While Gln192, and His164 residues mediate two hydrogen bonds with oxygen of sulfonamide group. The Glu166 mediates one hydrogen bond with side chain of nitrogen and oxygen of sulfonamide group. Additionally, Met165, Met49, Asp187, and His164 mediate hydrophobic interactions (Fig. 5A).

Furthermore, Pibrentasvir compound formed multiple hydrogen bonds, one with Gly143 (backbone hydrogen donor to oxygen of side chain), one hydrogen bond with His164 (hydrogen donor at nitrogen of benzimidazole ring), one hydrogen bond through Cys145 (accept hydrogen from nitrogen of same benzimidazole ring), and one hydrogen bond with Gln166 act as hydrogen acceptor from nitrogen of heterocyclic ring (Supplementary Fig. S2). The estimated docked score of Pibrentasvir was found as -8.31 kcal/mol.

Boceprevir showed good estimated docking score (i.e. -9.33 kcal/mol) and mediated six hydrogen bonds with Cys145, Gly143, His41 and Asn142 amino acids by oxygen atoms of side chain while His164 formed one hydrogen bond with nitrogen atom of heterocycle. Additionally, Met165 mediates hydrogen bond with carbonyl oxygen of side chain (Supplementary Fig. S3).

The estimated binding energy of Dasabuvir was found as -9.25 Kcal/mol. It mediates two hydrogen bonds with Asn142, and Phe140 as backbone hydrogen donor and acceptor to oxygen and nitrogen of thiol group present at the side chain of dasabuvir (Supplementary Fig. S4).

Glecaprevir was found to form three hydrogen bonds through oxygen of thiol group with Thr26, Gly143 (as backbone hydrogen acceptor), and Leu27 as side chain hydrogen acceptor. While Cys145 mediates one hydrogen bond with nitrogen of sulfonamide side chain. Whereas His164 mediates one hydrogen bond as backbone hydrogen acceptor from nitrogen of heterocyclic ring (Supplementary Fig. S5). Additionally, 3D interaction showed that Gln166 mediates hydrogen bond with Glecaprevir. The estimated binding energy of -9.64 Kcal/mol was observed.

Paritaprevir set well in the binding side of Mpro protein with an estimated docking score of -11.42 Kcal/mol. It mediated four hydrogen bonds with Glu166 through different nitrogens of side chain. While Pro168 mediates two hydrogen bonds with nitrogen and oxygen, and Phe140 mediates aromatic-hydrogen bond with nitrogen quinoline ring of paritaprevir (Fig. 5B).

The docking study of Ribavirin showed the estimated binding energy of -5.35 Kcal/mol. Ribavirin mediates three hydrogen bonds with Thr26, Gly143, and Leu141 as backbone hydrogen donor and

| S. No. | DAAs   | Binding Energies | Kᵦ (μm) | predicted (μm) |
|-------|--------|------------------|---------|---------------|
| 1     | Beclabuvir | -11.97          | 1.67    |               |
| 2     | Boceprevir  | -9.33            | 145.61  |               |
| 3     | Dasabuvir   | -9.25            | 164.81  |               |
| 4     | Glecaprevir  | -9.64            | 85.37   |               |
| 5     | Paritaprevir | -11.42          | 4.28    |               |
| 6     | Pibrentasvir| -8.31            | 805.13  |               |
| 7     | Ribavirin   | -5.35            | 118.94  |               |
| 8     | Ritonavir   | -8.27            | 873.55  |               |
| 9     | Telaprevir  | -9.04            | 234.71  |               |
| 10    | Velpatasvir  | -9.4             | 139.84  |               |
| 11    | Voxlaprevir  | -8.77            | 409.85  |               |
| 12    | Asunaprevir  | -9.99            | 47.66   |               |
| 13    | Daclatasvir  | -6.75            | 11.35   |               |
| 14    | Elbasvir    | -11.92           | 1.82    |               |
| 15    | Faldaprevir  | -7.60            | 2.68    |               |
| 16    | Omitasvir   | -6.85            | 9.57    |               |
| 17    | Grazoprevir  | -11.37           | 4.63    |               |
| 18    | Simeprevir   | -9.07            | 10.35   |               |
| 19    | Sofosbuvir   | -9.43            | 122.22  |               |
| 20    | Ledipasvir  | -8.46            | 624.28  |               |
| 21    | Test        | -9.71            | 76.50   |               |
acceptor to nitrogen and oxygen of oxole (furan) ring. Additionally, His41, and Cys145 mediate four hydrogen bonds as side chain hydrogen donor and acceptor with nitrogen of triazole and oxygens of furan ring of Ribavirin (Supplementary Fig. S6).

The docking study for Ritonavir showed better alignment at the active site of Mpro with an estimated binding energy of -8.27 Kcal/mol. It formed total of four hydrogen bonds with significant active site residues. It mediates two hydrogen bonds as acidic and basic hydrogen acceptor from Asn142, and Cys145 through side chain thiazole ring. The Glu166 amino acid mediates one hydrogen bond as basic through nitrogen of side chain aromatic ring while Phe140 mediates one hydrogen bond as basic acceptor (Supplementary Fig. S7).

Docking study highlights that Telaprevir mediates four hydrogen bonds with Mpro protein showing significant binding energy score of -9.04 Kcal/mol. The Met165 mediates one hydrogen bond with oxygen while Glu166 mediates two hydrogen bonds as backbone hydrogen acceptor to oxygen and nitrogen of cyclopropane ring, respectively (Supplementary Fig. S8).

It was observed through docking analysis that Velpatasvir formed interactions with an estimated binding energy of -9.4 Kcal/mol. It mediates multiple hydrogen bonds as backbone hydrogen donor to Gly143, Thr26 and Glu166. Additionally, it has made an aren - H interaction between the heterocyclic aromatic ring of Velpatasvir and the Thr26. (Supplementary Fig. S9).

The docking study of Voxilaprevir revealed that it mediates two hydrogen bonds with Mpro protein. It was found that Gln189 and His41 act as hydrogen bond partners with the Voxilaprevir atoms. The docking score calculated for voxilaprevir was -8.77 Kcal/mol (Supplementary Fig. S10).

Asunaprevir mediates ten hydrogen bonds with an estimated binding energy of -9.99 Kcal/mol. The docking study highlights that Glu166 formed two hydrogen bonds between quinolone ring as a hydrogen donor (side chain hydrogen donor). The same Glu166 mediates one hydrogen bond with side chain oxygen of pyrrole ring as backbone hydrogen donor with a distance of 2.95 Å. While His41, Cys145, and Asn142 interact with oxygens of sulfonamide group, nitrogen found at side chain and chlorine of quinolone ring through hydrogen bonds having a bond distance of 3.16 and 3.05 Å, respectively. Furthermore, Ser144 and Gly143 mediate three hydrogen bonds as backbone hydrogen donor to oxygen of sulfonamide group with the bond distance of 3.04, 2.81, and 2.95 Å, respectively (Supplementary Fig. S11).

The docked structure of Daclatasvir showed estimated binding energy as -6.75 Kcal/mol. The study showed it mediates one hydrogen bond with Mpro protein through Leu27 interacting with imidazole ring (Supplementary Fig. S12).

Elbasvir drug facilitates significant interaction with Mpro protein resulting in the second highest estimated binding energy of -11.92 Kcal/mol. It mediates multiple hydrogen bonds with different active site residues. Thr26 acts as backbone hydrogen acceptor, mediating one hydrogen bond with nitrogen. Glu166 was found to mediate three hydrogen bonds with imidazole ring as side chain and backbone hydrogen acceptor to Elbasvir (Fig. 5C).

The docked structure of Faldaprevir showed estimated binding energy of -7.60 Kcal/mol. It mediated two hydrogen bonds as side chain and backbone acceptor with Cys145. Glu166 was found to intermediate one hydrogen bond with oxygen of quinolone ring, while Gln189 formed one hydrogen bond as side chain hydrogen acceptor to carboxylic oxygen adjacent to cyclopropane ring (Supplementary Fig. S13).

Grazoprevir exhibited one of the most significant binding energy estimated as -11.37 Kcal/mol. The docking study revealed that Grazoprevir mediate multiple hydrogen bonds as hydrogen acceptor and donor (from backbone) with Gly143, His164 and Cys145 residues to the oxygen of sulfonamide group (Fig. 5D).

Simeprevir exhibited the estimated binding energy of -9.07 Kcal/mol resulting in the most stable interaction with Mpro protein. It mediates multiple hydrogen bonds with different significant active side residues. Met165 and Gln189 are mediating at least two hydrogen bonds with oxygen of sulfonamide group. On the other hands, Cys145 is making a close proximal interaction with the nitrogen atom of the ligand Simeprevir (Supplementary Fig. S14).

Furthermore, Sofosbuvir was also found to mediate multiple hydrogen bonds with Mpro proteins showing binding energy of -9.43 Kcal/mol. It was observed that Cys145 and Gly143 mediate hydrogen bonds with oxygen of heterocyclic ring as backbone hydrogen donor while Phe140 and His163 mediate hydrogen bond as side chain hydrogen donor to heterocyclic oxygen, whereas, Ser144 mediates hydrogen bond as side chain hydrogen acceptor to nitrogen of heterocyclic ring. Additionally, Glu166 and Met165 mediate hydrogen bonds with oxygen of phosphate group of Sofosbuvir (Supplementary Fig. S15).

Nevertheless, Ledipasvir drug mediates two hydrogen bonds as side chain hydrogen acceptor with Gln186 through oxygen, and

Fig. 5. Analysis of docked compounds showing significant interactions with Mpro active site. (A) Beclabuvir, (B) Paritaprevir, (C) Elbasvir, (D) Grazoprevir, and (E) reference compound (osik) highlighting the 3D and 2D interactions.
Table 3
Identified IC₅₀ through literature for eight compounds.

| S.No | DAAs       | Binding Energies | IC₅₀ identified through Literature Mining (µm) | References |
|------|------------|------------------|-----------------------------------------------|------------|
| 1    | Boceprevir | -9.33            | 19.6                                          | [3]        |
| 2    | Paritaprevir| -11.42           | 73.38                                         |            |
| 3    | Ritonavir  | -8.27            | 13.4                                          | [14]       |
| 4    | Telaprevir | -9.04            | 15.25                                         | [3]        |
| 5    | Asunaprevir| -9.99            | 15                                            | [3]        |
| 6    | Omitasvir  | -6.85            | 75.49                                         | [18]       |
| 7    | Grazoprevir| -11.37           | 10.8                                          | [2]        |
| 8    | Simeprevir | -9.07            | 4.25                                          | [3]        |

Table 4
Detail analysis of molecular docking studies.

| S. No | DAAs     | No of Hydrogen Bonds | Residues of Active Site               |
|-------|----------|----------------------|--------------------------------------|
| 1     | Beclabuvir| 6                    | Gln192, Asn142, and His164           |
| 2     | Boceprevir| 6                    | Cys145, Gly143, His41, Met165 and Asn142|
| 3     | Dasabuvir | 2                    | Asn142, and Phe140                    |
| 4     | Glecaprevir| 6                   | Thr26, Leu27, Cys145, Glu166, and Gly143|
| 5     | Paritaprevir| 5                   | Gly143, Asn142, His164, and Cys145    |
| 6     | Pibrentasvir| 5                   | Gly143, Asn142, His164, Cys145, and Glu166|
| 7     | Ribavirin | 7                    | Thr26, Gly143, Cys145, His41, and Leu141|
| 8     | Ritonavir | 4                    | Glu166, Asn142, Cys145, and Phe140     |
| 9     | Telaprevir| 4                    | Asn142, Met165, and Glu166            |
| 10    | Velpatasvir| 3                   | Thr26, Gly143, and Glu166             |
| 11    | Voulaprevir| 2                   | His41, and Gln189                     |
| 12    | Asunaprevir| 10                  | Gln166, His41, Cys145, Ser144, Gly143, and Asn142 |
| 13    | Daclatasvir| 2                   | Leu27, and Thr25                      |
| 14    | Elbasvir  | 6                    | Thr26, Thr24, Pro168, Leu167, and Glu166|
| 15    | Faldaprevir| 4                   | Cys145, Glu166, and Gln189            |
| 16    | Omitasvir | 3                    | Gln166, and Asn142                    |
| 17    | Grazoprevir| 4                   | Thr26, Gly143, Asn142, and Cys145     |
| 18    | Simeprevir| 3                    | Gln189, Met165, and Asn142            |
| 19    | Sofosbuvir| 8                    | Cys145, Gly143, Phe140, His163, Ser144, His14, Glu166 and Met165 |
| 20    | Ledipasvir| 5                    | Cys145, Met49, Gln186, Phe140, Met165, and Glu166 |
| 21    | Test     | 7                    | Ser144, Cys145, Met165, and His164     |

with Cys145 through oxygen of side chain, while two hydrogen-arene (aromatic) bonds were formed with Glu166 and Met165 amino acid with aromatic and imidazole ring of Ledipasvir, respectively. Additionally, Phe140 mediates one hydrogen bond with oxygen atom of side chain. The bonding energy calculated for Ledipasvir against Mpro was estimated as -8.46 Kcal/mol (Supplementary Fig. S16).

Simultaneously, the redocking study was performed to validate our docking results for DAAs against Mpro protein. The docking analysis for o6k (as test compound) showed significant interaction with active site residues of Mpro with -9.71 Kcal/mol binding energy. It has mediated total of seven hydrogen bonds with active amino acids. Ser144 formed one hydrogen bond with oxygen of side chain, Cys145 formed two hydrogen bonds with oxygen as hydrogen acceptor and donor, Met165 formed one hydrogen bond with nitrogen of pyrrole ring, while His164 formed one hydrogen bond with oxygen of pyrrole ring and the other with hydroxyl group (Fig. 5E).

The docking study revealed that compounds Beclabuvir, Paritaprevir, Asunaprevir, Elbasvir, Grazoprevir, and Simeprevir have shown high binding energies i.e. from -9.9 to -11 Kcal/mol (i.e. greater than test compound). The complete binding interactions of DAAs with Mpro proteins are presented in Table 4.

3.2. Correlation identification between IC₅₀ and binding energies

In the current study, the correlation between IC₅₀ (identified through literature mining) and calculated binding energies was also investigated. The IC₅₀’s for eight compounds out of twenty DAAs against Mpro enzyme were found in whole cell culture. The Table 3 reported the IC₅₀ of each compound and the corresponding source reference. The correlation predicted for these eight compounds along with their binding energies was estimated to be 0.725 (Fig. 6). This high correlation classified this study as significant. The correlation identification helped to find a relation that lower the binding energy (i.e. higher negative value), lower will be the IC₅₀ value. The significant relationship between the IC₅₀ and binding energies provides an insight for further prediction of IC₅₀ of unknown compounds.

4. Discussion

The current pandemic coronavirus disease 2019 (SARS-CoV-2, previously known as 2019-nCoV) is classified as serious global threat to humans resulting in 54 million confirmed cases, growing at rates of up to 600,000 new cases/day while over 181,000 deaths [8] (as of 24 April 2020) with an estimated fatality rate of 3% (Worldometer 2020, https://www.worldometers.info/coronavirus/). This pandemic emerged as deadly disease that is damaging the alveoli, resulting in respiratory failure and subsequent death. Due to barely accessible affected patient’s report of biopsy and autopsy, the pathology of COVID disease is unclear. Despite numerous approaches (such as personal protection, social distancing, and disinfection), all treatments measure that employed anti-inflammatory and antiviral are supportive to only treat the symptoms of COVID disease, while no specific antiviral drugs have been confirmed to be effective yet [6]. The greatest challenge today is to effectively control the spread of the pandemic until a successful vaccine is available [16].

The Direct Acting Antivirals (DAAs) are newly emerged class of antivirals used for the treatment of HCV [15]. The DAAs inhibit the NS3/4A protease, the NS5A protein, and the NS5B polymerase proteins of HCV providing an effective treatment approach. The DAAs have revolutionized the HCV treatment based on their favorable
side effects profiles and enhanced rates of sustained virological response. The Mpro (Main Protease) is classified as one of the key enzymes responsible for the replication and transcription of coronavirus. Accordingly, Mpro could be an interesting target to explore the efficacy of any drug against coronavirus. Due to the similarities found in HCV and SARS-CoV2 genomics and proteomics, the drug repurposing of DAAs against Mpro of COVID was applied in the current study [4].

This study was aimed to consider DAAs (due to the striking activity against the HCV protease) against Mpro from SARS-CoV-2 and proposed them to be evaluated against COVID-19. The repurposed drugs can skip the prior screening and could move directly to the clinical trials and approved by the FDA for an immediate indication [5]. The DAAs of HCV such as Beclabuvir, Boceprevir, Dasabuvir, Glecaprevir, Paritaprevir, Pibrentasvir, Ribavirin, Ritonavir, Telaprevir, Velpatasvir, Asunaprevir, Voxilaprevir, Daclatasvir, Elbasvir, Faldaprevir, Omitasvir, Grazoprevir, Simeprevir, Sofosbuvir, and Ledipasvir were tested in silico for their potential as a treatment for COVID-19. Earlier, successful repurposed drugs have been approved such as use of Aspirin for the treatment of coronary artery diseases and the use of Sildenafil to treat erectile dysfunction [23].

Herein, the docking study of selected twenty DAAs was conducted against Mpro through AutoDock along with the crystalized ligand as reference compound to identify novel compounds against Mpro and validate the current study. The docking study revealed that all compounds were computationally predicted with the lowest binding energies ranging from $-4$ to $-11$ Kcal/mol, and formed stable interactions through intermolecular hydrogen bonds. It was found that six compounds i.e. Beclabuvir, Paritaprevir, Asunaprevir, Elbasvir, Grazoprevir, and Simeprevir showed standard minimum binding energies of $-9.9$ to $-11.9$ Kcal/mol compared with the reference compound (i.e. $-9.7$ Kcal/mol) and they exhibited tight interactions against Mpro with stable docking and higher binding energies. Paritaprevir, Asunaprevir, Grazoprevir, and Simeprevir are protease inhibitors (for HCV), Beclabuvir is a non-nucleoside polymerase inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B), while Elbasvir is hepatitis C virus nonstructural protein 5A inhibitor [25].

To get insight into the intermolecular interactions, the molecular docking studies were further analyzed through MOE tool. The post docking analysis of these compounds showed that most of the hydrogen bonds formed between DAAs and Mpro mediates the involvement of GLU166, CYS145, MET165, ASN142, H1541, THR26, and HIS164 active site residues reported as most significant amino acids present at the active site of Mpro enzyme. In addition, our findings may help in understanding the structure and activity relationship requirements for Mpro targeting drugs. For example, the essential role of the pyrimidine moiety and imidazole moiety in the six prioritized compounds were found as mediating the most significant hydrogen bonds with the crucial amino acids of the active site through its azole and pyrrolidine rings. This finding may help to innovate the new drug candidates against COVID-19. Furthermore, the docked binding energies and IC$_{50}$ through literature survey were examined to find the correlation among them. It was observed through correlation analysis that the higher negative binding energy value resulted in lower IC$_{50}$ value.

Finally, this study found a correlation among the affinities of the tested anti-HCV drugs against COVID-19 protease. Accordingly, we suggest such drugs for the repurposing pathway to reach an effective therapy for pandemic COVID-19. Furthermore, these drugs could be used either alone or in combination with each other’s or with interferons as in the case with the Hepatitis C virus.

5. Conclusion

The emergence of COVID-19 variants is a major bottle-neck in the discovery of a successful molecular therapeutic. Therefore, understanding of the molecular basis of the available FDA approved drugs is a key to find new treatment options. The successful application of DAAs against HCV grabs the attention to try them against COVID-19 also. Hence, twenty DAAs of HCV were subjected to molecular docking against SARS-CoV-2 main protease. The docking analysis revealed the variable affinities of these DAAs
towards SARS-CoV-2 Mpro compared to the 6GK reference compound. However, the six shortlisted DAA s are recommended for further clinical testing against COVID-19. Nevertheless, before clinical recommendations of these six shortlisted DAA s against COVID-19, it is highly recommended to conduct larger, dose determining, randomized, and prospective controlled clinical trial.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

CRediT authorship contribution statement

**Reaz Uddin:** Conceptualization, Methodology, Software, Visualization, Investigation, Supervision, Writing – review & editing.

**Khurshid Jalal:** Data curation, Writing – original draft.

**Kanwal Khan:** Data curation, Writing – original draft.

**Zaheer ul-Haq:** Visualization, Investigation.

Acknowledgments

The authors would like to acknowledge the International Foundation for Science (IFS) for providing the research grant # I-1-F-5378-2.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.molstruc.2021.131920.

References

[1] A.A. Al-Karmalawy, R. Alnajjar, M. Dahab, A. Metwally, I. Eissa, Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease, Pharm. Sci. 30 (2021) 1–27.

[2] K. Anand, G.J. Palm, J.R. Mesters, S.G. Siddle, J. Ziebuhr, R. Hilgenfeld, Structure of coronavirus main protease reveals combination of a chymotrypsin fold with an extra α-helical domain, EMBO J. 21 (13) (2002) 3213–3224.

[3] Bafna, K., Krug, R.M., & Montelione, G.T., 2020. Structural similarity of SARS-CoV-2 Mpro and HCV NS3/4A proteases suggests new approaches for identifying existing drugs useful as COVID-19 therapeutics. ChemRxiv. doi:10.26434/chemrxiv.

[4] K. Bafna, K. White, B. Harish, R. Rosales, T.A. Ramelot, T.B. Acton, E. Moreno, T. Kehrer, L. Miorin, C.A. Royer, Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture, Cell Rep. 35 (7) (2021) 109133.

[5] S. Chakraborti, S. Bheemreddy, N. Sinivasan, Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data, Mol. Omics 16 (5) (2020) 474–491.

[6] E.W. Chan, Currrent and future direct-acting antivirals against COVID-19, Front. Microbiol. 11 (2020) 2880.

[7] K.A. Gammeltoft, Y. Zhou, C.R. Duarte Hernandez, A. Galli, A. Offergaard, R. Costa, L.V. Pham, U. Fahnæs, S. Peng, T.K. Scheel, Hepatitis C virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in vitro, Antimicrob. Agents Chemother. AAC (2020) 02680-02620.

[8] A.B. Gurung, In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors, Gene Rep. 21 (2020) 100860.

[9] M. Hamed, M. El-Hasab, F.R. Mansour, Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors, Virussdisease 32 (2021) 279–285.

[10] R. Huey, G.M. Morris, S. Forli, in: Using AutoDock 4 and AutoDock vina with AutoDockTools: A Tutorial, 10550, The Scripps Research Institute Molecular Graphics Laboratory, 2012, p. 92037.

[11] A. Izz, V. Messina, L. Rinaldi, P. Maggi, Editorial–Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV-2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents, Eur. Rev. Med. Pharmacol. Sci. 24 (10) (2020) 5193–5194.

[12] Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Structure of Mpro from covid-19 virus and discovery of its inhibitors, Nature Sci. (2020) 289–293.

[13] M.B. Libib, J.N. Phililpes, P.F. Lamie, E.R. Ahmed, Azole-azole derivatives: design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents, Bioorg. Chem. 76 (2018) 67–80.

[14] M. Malhi, J.A. Mótyán, Z.i. Szokja, M. Golda, M. Micz, J. Tóthé, Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2’s main protease, Virol. J. 17 (1) (2020) 1–8.

[15] A.M. Matthew, F. Leidner, G.J. Lockbaum, M. Henes, J. Zephyr, S. Hou, D.N. Rao, J. Timm, L.N. Rusere, D.A. Ragland, Drug design strategies to avoid resistance in direct-acting antivirals and beyond, Chem. Rev. 121 (6) (2021) 3238–3270.

[16] H.M. Mengist, D. Meckonen, A. Mohammed, R. Shi, T. Jin, Potency, safety, and pharmacokinetic profiles of potential inhibitors targeting SARS-CoV-2 main protease, Front. Pharmacol. 11 (2021) 2495.

[17] M.A. Miteva, F. Guyon, P. Tuffery, Frog2: efficient 3D conformation ensemble generator for small compounds, Nucleic Acids Res. 38 (suppl_2) (2010) W622–W627.

[18] V. Mody, J. Ho, S. Wills, A. Mawri, L. Watson, M.C. Ebert, G.M. Fortin, S. Rayalam, S. Taval, Identification of 3-chymotrypsin like protease (3CLpro) inhibitors as potential anti-SARS-CoV-2 agents, Commun. Biol. 4 (1) (2021) 1–10.

[19] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility, J. Comput. Chem. 30 (16) (2009) 2785–2791.

[20] J.M. Pawlotsky, COVID-19 pandemic: time to revive the cyclophillin inhibitor alisporivin, Clin. Infect. Dis. 71 (16) (2021) 2191–2194.

[21] S. Pelly, D. Liotta, Potent SARS-CoV-2 direct-acting antivirals provide an important complement to COVID-19 vaccines, ACS Cent. Sci. 7 (3) (2021) 396–399.

[22] Y. Rose, J.M. Duarte, R. Lowe, J. Segura, C. Bi, C. Bhikadiya, L. Chen, A.S. Rose, S. Bittrich, S.K. Burley, RCSB Protein Data Bank: architectural advances towards integrated searching and efficient access to macromolecular structure data from the PDB archive, J. Mol. Biol. 433 (11) (2021) 166704.

[23] Rudrapal, M., Khairnar, J., & Jadhav, G. (2020). Drug repurposing (dr): an emerging approach in drug discovery. London, UK.

[24] W. Song, M. Gui, X. Wang, Y. Xiang, Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2, PLoS Pathog. 14 (8) (2018) e1007236.

[25] D.S. Wishart, Y.D. Feunang, A.C. Guo, E.J. Lo, A. Marcu, J.R. Grant, T. Sajed, D. Johnson, C. Li, Z. Sayeda, DrugBank 5.0: a major update to the DrugBank database for 2018, Nucleic Acids Res. 46 (D1) (2018) D1074–D1082.

[26] P. Wu, S. Zhao, B. Yu, Y.M. Chen, W. Wang, Z.G. Song, Y. Hu, Z.W. Tao, J.H. Tian, Y.Y. Pei, A new coronavirus associated with human respiratory disease in China, Nature 579 (7798) (2020) 265–269.

[27] L. Zhang, D. Lin, X. Sun, U. Curti, C. Drosten, L. Sauerhering, S. Becker, K. Rox, R. Hilgenfeld, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors, Science 368 (6489) (2020) 409–412.